Home
 
to Order
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
































 

On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil

Saletu B; Saletu M; Grunberger J; 
Frey R; Zatschek I; Mader R

Department of Psychiatry, 
University of Vienna, Austria.
Prog Neuropsychopharmacol Biol Psychiatry, 14(2):195-214 1990

Abstract:

1. In a double-blind study forty abstinent hospitalized male patients with an alcoholic organic brain syndrome (OBS) were treated for 6 weeks with either 200 mg modafinil or placebo.

2. Modafinil (CRL 40476) is a putative central alpha-1 adrenergic agonist.  It's pharmacological profile is quite different from that of amphetamine, which can be seen by the lack of peripheral sympathomimetic effects.  The vigilance promoting effect of modafinil has been shown previously in pharmaco-EEG and psychometric studies as well as in clinical studies involving treatment of daytime sleepiness in idiopathic hypersomniacs and narcoleptics.

3. The present clinical investigations demonstrated that the spontaneous restitution of the alcoholic OBS was significantly augmented and accelerated by modafinil.

4. Psychometric tests did not show significant intergroup differences.  Modafinil- and placebo-treated patients improved continuously over the 6-week period.

5. Psychophysiological and autonomous nervous system parameters were affected neither by placebo nor by modafinil.

6. Neurophysiological investigations by means of quantitative pharmaco-EEG showed partly inconsistent findings. However, superimposed dosages of modafinil (on the top of 6 weeks chronic administration) induced a decrease of slow activity and an increase of alpha activity suggesting an improvement of vigilance after the daily drug intake. 

7. Considering the beneficial effects of modafinil in abstinent chronic alcoholic patients, it may be said that activation and improvement of adaptive behaviour by an alpha-adrenergic agonist could be regarded as a therapeutic principle in the treatment of the OBS, eventually due to noradrenergic deficits.

Home | Order

 1.   Modafinil  augmentation of antidepressant treatment
 2.   Modafinil  children with attention-deficit/hyperactivity disorder
 3.   Modafinil  in fibromyalgia treatment
 4.   Modafinil  efficacy in narcolepsy
 5.   Modafinil  narcolepsy: symptoms and management
 6.   Modafinil  successful treatment of hypersomnia & narcolepsy
 7.   Modafinil  drug of choice for narcolepsy
 8.   Modafinil  in the treatment of narcolepsy
 9.   Modafinil  effect on narcolepsy
10.  Modafinil  a narcolepsy study
11.  Modafinil  switching from narcolepsy drugs to modafinil
12.  Modafinil  and naps as counter measures in sleep deprivation
13.  Modafinil  as a treatment for excessive daytime sleepiness
14.  Modafinil  use in a sleep deprivation experiment
15.  Modafinil  excessive sleepiness in Parkinson's disease
16.  Modafinil  the unique properties of a new stimulant 
17.  Modafinil  for sustaining the alertness of helicopter pilots
18.  Modafinil  dosage and safety
19.  Modafinil  treatment of alcoholic organic brain syndrome
20.  Modafinil  effect on melatonin, cortisol, and growth hormone
21.  Modafinil  in obstructive sleep apnea-hypopnea syndrome
22.  Modafinil  vs dextroamphetamine in treatment of adult ADHD
23.  Modafinil  dopaminergic transmission mediates CNS stimulants
24.  Modafinil  for daytime sleepiness in sleep apnea
25.  Modafinil  treatment of residual excessive daytime sleepiness
26.  Modafinil  amplification of cortical serotonin release
27.  Modafinil  for the treatment of multiple sclerosis

 

 

 

Hit Counter